Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REP 2055 in Chronic HBV or HCV
NCT02646163Phase 2Completed
- Sponsor
- Replicor Inc.
- Start
- Jan 2009
- Primary completion
- Dec 2012
- Modality
- Antisense DNA, RNA Aptamers, Modified DNA Aptamers
- Countries
- 1
01
Overview
A Phase 2 trial of REP 2055 in Chronic Hepatitis B (CHB), hepatitis C (HCV), sponsored by Replicor Inc.. Started Jan 2009; status: completed.
02
Drugs
REP 2055
03
Conditions
Chronic Hepatitis B (CHB)hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02646163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02646163.